Vinva Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Vinva Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.22M	Sell	9,531 -1,407	-13%	-$656K	0.05%	228
2025 Q4	$4.96M	Buy	10,938 +2,303	+27%	+$993K	0.06%	208
2025 Q3	$3.41M	Sell	8,635 -1,710	-17%	-$715K	0.07%	219
2025 Q2	$4.57M	Sell	10,345 -2,792	-21%	-$1.29M	0.12%	173
2025 Q1	$6.47M	Buy	13,137 +9,625	+274%	+$4.49M	0.26%	101
2024 Q4	$1.4M	Buy	3,512 +1,069	+44%	+$496K	0.05%	260
2024 Q3	$1.13M	Sell	2,443 -6,784	-74%	-$3.26M	0.05%	280
2024 Q2	$4.36M	Sell	9,227 -479	-5%	-$208K	0.22%	113
2024 Q1	$4.06M	Buy	9,706 +703	+8%	+$297K	0.23%	113
2023 Q4	$3.68M	Buy	9,003 +1,006	+13%	+$372K	0.25%	101
2023 Q3	$2.82M	Buy	7,997 +121	+2%	+$42.3K	0.26%	89
2023 Q2	$2.74M	Sell	7,876 -881	-10%	-$297K	0.24%	106
2023 Q1	$2.73M	Buy	+8,757	New	+$2.63M	0.23%	116

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vinva Investment Management's VRTX Position: Q1 2026 in Review

Vinva Investment Management reduced its Vertex Pharmaceuticals (VRTX) stake by 13% in Q1 2026, selling an estimated $656K and leaving 9,531 shares worth $4.22M. The position accounts for 0.05% of the portfolio, ranked #228.

Vinva Investment Management first reported a position in VRTX in Q1 2023 and has held it in 13 quarters since. The position peaked at $6.47M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Vinva Investment Management held 9,531 shares of Vertex Pharmaceuticals worth $4.22M as of Q1 2026.
Vinva Investment Management sold 1,407 Vertex Pharmaceuticals shares in Q1 2026, an estimated $656K.
Vertex Pharmaceuticals made up 0.05% of Vinva Investment Management's portfolio in Q1 2026, its #228 holding.
Vinva Investment Management first reported a position in Vertex Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
Vinva Investment Management's Vertex Pharmaceuticals position peaked at $6.47M in Q1 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Vinva Investment Management's 13F filing for Q1 2026, filed 14 May 2026.